Cargando…
Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes
BACKGROUND: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy. METHODS: Newly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) wer...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039101/ https://www.ncbi.nlm.nih.gov/pubmed/24883155 http://dx.doi.org/10.14740/jocmr1841e |
_version_ | 1782318441499197440 |
---|---|
author | Kutoh, Eiji Hirate, Mitsuru Ikeno, Yu |
author_facet | Kutoh, Eiji Hirate, Mitsuru Ikeno, Yu |
author_sort | Kutoh, Eiji |
collection | PubMed |
description | BACKGROUND: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy. METHODS: Newly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) were assigned to 20 mg/day teneligliptin monotherapy (n = 31). At 3 months, levels of glycemic and other parameters were compared with those at baseline. RESULTS: Significant reductions of HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%) and fasting blood glucose (FGB, from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL) levels were observed without any clinically significant adverse events. However, significant increases of uric acids (UA) levels were observed and two subjects reported mild hypoglycemic events. Homeostasis model assessment-B (HOMA-B) levels significantly increased, while high HOMA-R levels significantly decreased. Significant correlations were observed between the changes (Δ) of HbA1c and those of HOMA-B, and between ΔFBG and ΔHOMA-R. No changes in lipid and body weight were noted. CONCLUSIONS: Teneligliptin might be effectively and safely used as an initial therapy for newly diagnosed T2DM. Glycemic efficacy of teneligliptin is obtained through activating beta-cell function as well as decreasing insulin resistance. |
format | Online Article Text |
id | pubmed-4039101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Elmer Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40391012014-05-30 Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes Kutoh, Eiji Hirate, Mitsuru Ikeno, Yu J Clin Med Res Original Article BACKGROUND: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy. METHODS: Newly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) were assigned to 20 mg/day teneligliptin monotherapy (n = 31). At 3 months, levels of glycemic and other parameters were compared with those at baseline. RESULTS: Significant reductions of HbA1c (from 10.34 ± 2.06 to 8.38 ± 2.23%) and fasting blood glucose (FGB, from 211.3 ± 68.4 to 167.3 ± 70.2 mg/dL) levels were observed without any clinically significant adverse events. However, significant increases of uric acids (UA) levels were observed and two subjects reported mild hypoglycemic events. Homeostasis model assessment-B (HOMA-B) levels significantly increased, while high HOMA-R levels significantly decreased. Significant correlations were observed between the changes (Δ) of HbA1c and those of HOMA-B, and between ΔFBG and ΔHOMA-R. No changes in lipid and body weight were noted. CONCLUSIONS: Teneligliptin might be effectively and safely used as an initial therapy for newly diagnosed T2DM. Glycemic efficacy of teneligliptin is obtained through activating beta-cell function as well as decreasing insulin resistance. Elmer Press 2014-08 2014-05-22 /pmc/articles/PMC4039101/ /pubmed/24883155 http://dx.doi.org/10.14740/jocmr1841e Text en Copyright 2014, Kutoh et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kutoh, Eiji Hirate, Mitsuru Ikeno, Yu Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title | Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title_full | Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title_fullStr | Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title_full_unstemmed | Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title_short | Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes |
title_sort | teneligliptin as an initial therapy for newly diagnosed, drug naive subjects with type 2 diabetes |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039101/ https://www.ncbi.nlm.nih.gov/pubmed/24883155 http://dx.doi.org/10.14740/jocmr1841e |
work_keys_str_mv | AT kutoheiji teneligliptinasaninitialtherapyfornewlydiagnoseddrugnaivesubjectswithtype2diabetes AT hiratemitsuru teneligliptinasaninitialtherapyfornewlydiagnoseddrugnaivesubjectswithtype2diabetes AT ikenoyu teneligliptinasaninitialtherapyfornewlydiagnoseddrugnaivesubjectswithtype2diabetes |